The FDA reprimanded Novo Nordisk for “serious violations” in failing to report serious side effects tied to its blockbuster GLP-1 drugs, including Ozempic and Wegovy. Investigators said the company didn’t report cases involving strokes, suicidality and patient deaths, raising concerns about systemic problems in its drug safety monitoring.
